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R557DispatchesCancer Metabolism: Feeding a Worm to Starve a TumorThe tumor suppressor Rb is known to have its hand in many pots. New findings
have added another pot to the mix— cell metabolism. This may lead to a better
understanding of Rb mutant phenotypes and Rb’s roles in oncogenesis.David S. Fay
It has been known for more than
80 years that cancer cells alter their use
of metabolic pathways as a means for
enhanced proliferation and survival
[1,2]. In fact, changes in intracellular
metabolism are now considered to be
one of the hallmarks of oncogenic
transformation, along with genomic
instability, hyperproliferation, evasion
of apoptosis, immortalization,
metastasis induction, and activation
of angiogenesis [3]. Such metabolic
adjustments are essential for tumor
cells to acquire sufficient sources of
energy and to generate the
biosynthetic building blocks required
for cell growth and division. A paper
recently published in Current Biology
by Cui et al. [4] provides novel links
between changes in metabolism
and the role of the well-known tumor
suppressor Rb.
The best-characterized metabolic
change associated with tumors, known
as the Warburg effect, refers to the
strong preference of many cancer
cells for glycolysis over oxidative
phosphorylation [1,2]. Although less
efficient in terms of producing ATP,
glycolysis has the advantage of
generating macromolecular precursors
that are required for growth as well as
antioxidants that are used to neutralize
reactive oxygen species created
during rapid proliferation. To offset
potential deficits in energy production,
cancer cells typically increase their
uptake of extracellular glucose. In
addition, cancer cells can display
enhanced glutamine uptake and
processing and exhibit increased lipid,
protein, and nucleotide biosynthesis
[1,2]. Also, many solid tumor cells
undergo adaptive physiological
changes triggered by hypoxia and
acidosis [5].
Only recently have direct
connections been established between
the altered metabolism of tumor cells
and the genetic changes associated
with cancer progression. Oncogenesand tumor suppressors that have been
implicated in metabolic transformation
include several key players in the
phosphatidylinositol 3-kinase (PI3K)
pathway, including PTEN, AKT, and
mTOR, mutations in which promote
glycolysis and glucose uptake [1–3,6].
In addition, the transcription factor
and tumor suppressor p53 regulates
metabolism by several independent
mechanisms, including activation of
PTEN, and loss of p53 is thought to
contribute significantly to the glycolytic
phenotype [1,2,6]. Finally, one of the
earliest identified oncogenes, MYC,
stimulates glutamine uptake and
metabolism and promotes glucose
internalization and glycolysis via
hypoxia-inducible factor 1 (HIF1),
a target of mTOR [1,6].
One of the most intensively studied
tumor suppressors is the
retinoblastoma protein pRb [7,8],
which is functionally inactivated in
most human cancers and has been
implicated in many cellular and
developmental processes that
contribute to its functions as a tumor
suppressor [3,9]. This includes the
well-established role of pRb in
repressing cell-cycle progression but
also encompasses functions relevant
to genome stability, differentiation,
quiescence, senescence, invasion,
and angiogenesis. Notably, studies in
non-mammalian systems, including
Caenorhabditis elegans, have
implicated pRb orthologs in biological
processes that correlate well with
reported roles of pRb in mammalian
tumor suppression. In C. elegans, for
example, the pRb ortholog, LIN-35,
regulates progression through the cell
cycle, differentiation, apoptosis,
morphogenesis, and growth factor
expression [10]. The recent paper by
Cui et al. [4] now demonstrates a novel
function for LIN-35/pRb in metabolic
control, which may also be relevant to
its role in humans as a tumor
suppressor.
In their natural environment,
C. elegans frequently encounterstarvation conditions, which require
compensatory changes to cellular
metabolism and developmental
programs. One key decision point
occurs after hatching: worms in the
first larval stage (L1) that are hatched
in the absence of food undergo a
developmental arrest referred to as
the L1 diapause. The survival of starved
L1 worms requires the activity of a
conserved insulin–IGF-1 signaling (IIS)
pathway, which indicates that the
regulation of metabolism is conserved
between C. elegans and higher
eukaryotes [11]. Cui et al. [4] showed
that the survival of starved L1 worms
also depended on LIN-35/pRb because
lin-35/Rb loss-of-function mutants
were markedly sensitive to nutrient
deprivation.
To gain insights into the mechanistic
basis for LIN-35/pRb-mediated
diapause survival, Cui et al. [4]
performed a microarray analysis to
compare wild-type and lin-35/Rb
mutants. Rather surprisingly, the
spectrum of genes that was regulated
by LIN-35/pRb differed quite
dramatically between fed and starved
L1 worms, suggesting that there are
categorically distinct functions for
LIN-35/pRb under different growth
conditions [12]. These findings indicate
that, although LIN-35/pRb does not
directly regulate most IIS pathway
components, LIN-35/pRb and the IIS
pathway co-regulate the expression
of 58 genes in a manner that is largely
antagonistic. However, genetic
and microarray data suggest that
LIN-35/pRb also promotes diapause
survival through several mechanisms
that are independent of the IIS
pathway. This latter contention is
supported by phenotypic analysis
showing that glucose supplementation
dramatically improved the survival
of starved IIS pathway mutants but
had only weak effects on lin-35/Rb
mutants.
With respect to other relevant
metabolic targets, LIN-35/pRb
repressed the expression of many
genes induced by toxins, pathogens,
and oxidative stress. However,



















Figure 1. Diagram of reported pRb family links to cellular metabolism.
pRb family members are: LIN-35, C. elegans; RBF1, D. melanogaster; pRb, mouse and human.
IIS, insulin–IGF-1 signaling; PI3K, phosphatidylinositol 3-kinase.
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are critical for redox homeostasis, and
lin-35/Rb mutants were hypersensitive
to oxidative stress during L1 diapause.
In addition, LIN-35/pRb controls the
expression of many genes that encode
mitochondrial respiratory chain
components, which may be important
mediators of the response to
starvation. More globally, under
conditions of nutrient deprivation,
LIN-35/pRb is required for maintaining
a transcriptional profile that is
consistent with starvation. In the
absence of LIN-35/pRb, starved
animals displayed expression profiles
that were more reminiscent of well-fed
worms, which (perhaps not
surprisingly) was deleterious for
survival.
Interestingly, the role of LIN-35/pRb
in L1 diapause survival is dependent
to a large extent on the expression of
LIN-35/pRb in neurons and, to a lesser
degree, in the intestine. In contrast,
expression of LIN-35/pRb in one of
the major tissues of the worm, the
hypodermis (epidermis), was not
essential for diapause survival. The
data did, however, suggest that tissues
other than neurons and the intestine
must also contribute to the role of
LIN-35/pRb in the starvation response.
Taken together, their findings indicate
that LIN-35/pRb normally promotes
diapause survival through a number ofdistinct metabolic pathways and in
multiple tissue types.
One limitation of this current study is
the reliance on microarray data in
accounting for the mechanistic role of
LIN-35/pRb in regulating the starvation
response. Given that LIN-35/pRb
differentially regulates more than 1,200
genes in starved L1 animals, it would,
however, be difficult to functionally
assess the contribution of individual
genes or gene classes in this process.
An important open question is whether
or not LIN-35/pRb directly regulates
genes implicated in the starvation
response. One hint that at least some of
the targets are direct is the observation
that worms that had reduced function
in the C. elegans E2F ortholog, efl-1,
were also somewhat hypersensitive to
L1 starvation. E2F transcription factors
are conserved binding partners of
pRb family members and together form
the core of several multisubunit
transcriptional repressor complexes
[7]. In addition, a comparison of
LIN-35/pRb transcriptional targets in
starved L1s with experimentally
verified LIN-35/pRb genomic binding
sites showed a significant overlap,
suggesting that regulation by
LIN-35/pRb may in some cases be
direct [13].
Admittedly, the role of LIN-35/pRb in
the starvation response could be a
unique feature of C. elegans. A paperby Nicolay et al. [14] published earlier
this year does, however, suggest that
a function for pRb in the starvation
response may be conserved.
Drosophila cells that are mutant for
rbf1, one of the two Rb homologs in
flies, are hypersensitive to fasting
conditions, as are intact fly larvae in
which rbf1 activity has been partially
inactivated. Furthermore, RBF1
regulates genes involved in glutamine
and nucleotide metabolism, a finding
supported by metabolic profiling of fly
larvae depleted for rbf1. The increased
demand for glutamine in rbf1-depleted
larvae is responsible for their
hypersensitivity to fasting conditions,
and rbf1-depleted tissues are also
vulnerable to oxidative stress. In
addition, Nicolay et al. [14]
demonstrated that in multiple human
cancer cell lines loss of Rb altered the
metabolism of glutamine, leading to
alterations in energy production, redox
balance, and nucleotide pools.
Additional recent reports have also
implicated pRb family members in
the control of metabolism. The
simultaneous loss of both rbf1 and
gig/TSC2, a negative regulator of TOR
signaling, results in the induction of cell
death in fly tissues and leads to a
synergistic increase in oxidative stress
in mammalian cells [15]. Moreover,
pRb, along with its binding partner
E2F1, has also been implicated in the
control of oxidative metabolism in fat
tissue, and targeted deletion of Rb
and associated factors in mice can
lead to severe metabolic alterations
[2,16–19]. Still other reports have
linked the pRb pathway to lipid
and oxidative metabolism and to
mitochondrial biogenesis [16,19,20].
Finally, pRb is regulated in part
through phosphorylation by AMP
kinase, a key regulator of cellular
energy homeostasis [19].
Although the relative impact of the
pRb pathway on cancer cell
metabolism still remains to be
determined, the findings by Cui et al.
[4], together with other studies, are
starting to build a compelling case
(Figure 1). Nevertheless, the effects of
pRb family members on metabolism
appear to be quite complex and, in
some instances, contradictory.
Interestingly, loss of Rb often appears
to render cells less fit to cope with
the metabolic requirements and
physiological stresses that are
encountered by tumor cells. This
may point to therapies based on
Dispatch
R559the metabolic vulnerabilities of
Rb-deficient tumors but also suggests
that cancer cells may be capable of
evolving the means to counter these
deficiencies.References
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the Embryo Inside OutLineage decisions in development are thought to be primarily due to differential
activation of transcription factors. However, cell position and subcellular
organization of signalling also play a role. New studies of the Hippo pathway
in the early mouse embryo show how.Miguel Manzanares1,*
and Tristan A. Rodriguez2,*
In the early mammalian embryo, the
first cell-fate decision leads to the
formation of the trophectoderm, which
will form the placenta, and the inner cell
mass, which will give rise to the embryo
proper and yolk sac. It has long been
proposed that the position in the
embryo of the cells that will form the
trophectoderm or the inner cell mass is
key to this specification event. The
reason behind this suggestion is that
when the trophectoderm and the inner
cell mass segregate, between the 8-cell
and 16-cell stage, the embryo
resembles a compacted ball of cells
with some cells positioned on the
outside surface of this ball and others
embedded inside it. Those cells that lie
on the outside will form the
trophectoderm and are polarised with
an apical domain enriched in proteins
such as the atypical protein kinase C(aPKC) and the polarity protein Par3. By
contrast, the cells that lie inside are
apolar and will go on to form the inner
cell mass (Figure 1) [1,2]. But how is this
difference translated into the activation
of trophectoderm and inner cell mass
specific gene expression? Two new
studies in this issue of Current Biology
by the groups of Hiroshi Sasaki [3] and
Janet Rossant [4] shed important new
light on this question.
The first clue for an involvement of
the Hippo pathway in mammalian
pre-implantation development came
from analysis of mice lacking the
transcription factor Tead4 [5,6]. Tead is
a member of the Hippo pathway, a
signalling system that is evolutionarily
conserved from Drosophila
melanogaster to mammals and
controls organ size through cell
proliferation [7,8]. When the pathway is
activated, the Tead co-factors Yap and
Taz (homologues of Drosophila Yorkie)
are phosphorylated and excluded fromthe nucleus, therefore preventing
transcription of target genes. In the
blastocyst, the Tead4 protein is present
in all nuclei; however, Yap is only
localised to the nucleus of outside
trophectoderm cells. Consequently,
Tead4 mutants specify an inner cell
mass but do not form a trophectoderm
and lack proper expression of key
regulators of the trophectoderm
lineage, such as Cdx2. Therefore,
activation of the Hippo pathway
represses the trophectoderm fate. The
protein kinases Lats1/2 (homologues
of Drosophila Warts), which
phosphorylate Yap/Taz, are crucial for
this process, but again show no
differential expression between inner
and outer cells [9].
These studies provided evidence for
an involvement of the Hippo pathway
in repressing trophectoderm fate in
inside cells [9], but several important
questions remained unanswered: first
of all, it had not been established if
Hippo signalling plays any part in the
specification of the inner cell mass.
An unequivocal answer to this question
is provided by the Rossant and
Sasaki groups,whoanalysed theeffects
of loss of function of two different Hippo
pathway components that had not
previously been studied during
pre-implantation development, Nf2
(the homologue of DrosophilaMerlin)
